MSH|^~\&|MAYO CLINIC DEPT. OF LAB MED AND PATHOLOGY|MAYO CLINIC DEPT. OF LAB MED AND PATHOLOGY^2.16.840.1.113883.3.2.12.1.1^ISO|KS-MAIN|251-KS-MAIN|20201020002809-0500||ORU^R01^ORU_R01|2020102005280914866432|P|2.5.1|||NE|NE|USA||||PHLabReport-NoAck^HL7^2.16.840.1.113883.9.11^ISO
SFT|Lawson^L^^^^MAYO RD&2.16.840.1.113883.3.2.12.1&ISO^XX^^^99999|6.1|Cloverleaf IE|9999||20101113
PID|1|replaced 3|||Arla414^Daniel959||19460101|M|||123 Home Street^^ASHLAND^KY^44101|US|^PRN^PH^^1^920^6732264|||||||||||||||||
ORC|RE|20Y289Y0001|F715041049|||||||||^VANGALA^SANDEEP|7002859||||||||Stormont-Vail Reg Med Ctr|1500 SW 10th Ave^^Topeka^KS^666041301|^WPN^PH^^1^785^3546949
OBR|1|20Y289Y0001^Placer Order Number^2.16.840.1.113883.3.2.12.1.99^ISO|F715041049^Filler Order Number^2.16.840.1.113883.3.2.12.1.1^ISO|^^^LYWB^Lyme Disease Ab, Immunoblot, S^L^^U|||202010150652|||7002859^Stormont-Vail Reg Med Ctr^7853546949||||||^VANGALA^SANDEEP||||||202010192325|||F
OBX|1|CE|6320-6^B burgdor IgG Ser Ql IB^LN^5744^IgG Immunoblot^L^2.40^U||260385009^Negative^SCT||Negative||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201019232300||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
OBX|2|ST|13502-0^B burgdor IgG Patrn Ser IB-Imp^LN^2992^IgG detected against:^L^2.40^U||p66,p18|^^^kDa^kDa^L^^V1|||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201019232300||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
OBX|3|CE|6321-4^B burgdor IgM Ser Ql IB^LN^23931^IgM Immunoblot^L^2.40^U||260385009^Negative^SCT||Negative||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201019232300||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
OBX|4|CE|13503-8^B burgdor IgM Patrn Ser IB-Imp^LN^23932^IgM detected against:^L^2.40^U||260413007^None^SCT|^^^kDa^kDa^L^^V1|||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201019232300||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
OBX|5|ST|12781-1^B burgdor Ab Patrn Ser IB-Imp^LN^6241^Interpretation^L^2.40^U||See comment for results||||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201019232300||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
NTE|1|L|Specific serologic response to B. burgdorferi infection is
NTE|2|L|not detected, but cannot rule out early infection during
NTE|3|L|which low or undetectable antibody levels to B. burgdorferi
NTE|4|L|may be present.  If clinically indicated, a new serum
NTE|5|L|specimen should be submitted in 7-14 days.
NTE|6|L|Per CDC criteria, the Lyme IgG Immunoblot is interpreted as
NTE|7|L|positive if IgG-class antibodies are detected to >=5 B.
NTE|8|L|burgdorferi proteins, and the Lyme IgM Immunoblot is
NTE|9|L|interpreted as positive if IgM-class antibodies are
NTE|10|L|detected to >=2 B. burgdorferi proteins. Immunoblot
NTE|11|L|patterns not meeting these criteria should not be
NTE|12|L|interpreted as positive. Epitopes from certain B.
NTE|13|L|burgdorferi proteins (e.g., p41) are conserved across other
NTE|14|L|bacteria, which may lead to the detection of IgM- and/or
NTE|15|L|IgG-class antibodies on the Lyme disease immunoblots in
NTE|16|L|patients without Lyme disease. Immunoblot should only be
NTE|17|L|ordered on specimens that are positive or equivocal by a
NTE|18|L|FDA-licensed Lyme disease antibody screening test (e.g.,
NTE|19|L|EIA). Results of the Lyme IgM immunoblot should not be
NTE|20|L|considered in patients with >= 30 days of symptoms.
SPM|1|20Y289Y0001&Placer_LIS&2.16.840.1.113883.3.2.12.1.99&ISO^F715041049&Mayo_LIS&2.16.840.113883.1.3.2.11.1&ISO||119364003^Serum specimen (specimen)^SCT^Serum^Serum^L^07/31/2012^v1|||||||P^Patient^HL70369^P^Patient^L^2.5.1^V1|1^{#}&Number&UCUM&unit&unit&L&1.1&V1|||||202010150652|202010162020
OBR|2|20Y289Y0001^Placer Order Number^2.16.840.1.113883.3.2.12.1.99^ISO|F715041049^Filler Order Number^2.16.840.1.113883.3.2.12.1.1^ISO|^^^LYME^Lyme Disease Serology, S^L^^U|||202010150652|||7002859^Stormont-Vail Reg Med Ctr^7853546949||||||^VANGALA^SANDEEP||||||202010162244|||F
OBX|1|CE|20449-5^B burgdor Ab Ser Ql IA^LN^LYME^Lyme Disease Serology, S^L^2.40^U||10828004^Positive^SCT||Negative||||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201016202000||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
NTE|1|L|Not diagnostic. Supplemental testing by immunoblot has
NTE|2|L|been ordered by reflex.
SPM|1|20Y289Y0001&Placer_LIS&2.16.840.1.113883.3.2.12.1.99&ISO^F715041049&Mayo_LIS&2.16.840.113883.1.3.2.11.1&ISO||119364003^Serum specimen (specimen)^SCT^Serum^Serum^L^07/31/2012^v1|||||||P^Patient^HL70369^P^Patient^L^2.5.1^V1|1^{#}&Number&UCUM&unit&unit&L&1.1&V1|||||202010150652|202010161412
OBR|3|20Y289Y0001^Placer Order Number^2.16.840.1.113883.3.2.12.1.99^ISO|F715041049^Filler Order Number^2.16.840.1.113883.3.2.12.1.1^ISO|^^^EHRC^Ehrlichia Chaffeensis (HME) Ab, IgG^L^^U|||202010150652|||7002859^Stormont-Vail Reg Med Ctr^7853546949||||||^VANGALA^SANDEEP||||||202010180746|||F
OBX|1|SN|47405-6^E chaffeensis IgG Titr Ser IF^LN^81478^Ehrlichia Chaffeensis (HME) Ab, IgG^L^2.40^U||^1^:^1024|{titer}^titer^UCUM^titer^titer^L^1.8.2^V1|<1:64|A^Abnormal^HL70078^A^Abnormal^L^2.7^V1|||F|||202010150652|24D1040592^Mayo Clinic Labs-Roch Superior Dr^L||||20201018074600||||MCLab-RO Superior Dr^A^^^^CLIA&2.16.840.1.113883.4.7&ISO^XX^^^24D1040592|3050 Superior Drive NW^Level 1^Rochester^MN^55901^USA^L
NTE|1|L|This test was developed using an analyte specific reagent.
NTE|2|L|Its performance characteristics were determined by Mayo
NTE|3|L|Clinic in a manner consistent with CLIA requirements. This
NTE|4|L|test has not been cleared or approved by the U.S. Food and
NTE|5|L|Drug Administration.
SPM|1|20Y289Y0001&Placer_LIS&2.16.840.1.113883.3.2.12.1.99&ISO^F715041049&Mayo_LIS&2.16.840.113883.1.3.2.11.1&ISO||119364003^Serum specimen (specimen)^SCT^Serum^Serum^L^07/31/2012^v1|||||||P^Patient^HL70369^P^Patient^L^2.5.1^V1|1^{#}&Number&UCUM&unit&unit&L&1.1&V1|||||202010150652|202010161412